echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Food News > Food Articles > The first new crown vaccine produced by insect cells has been approved for clinical trials

    The first new crown vaccine produced by insect cells has been approved for clinical trials

    • Last Update: 2021-03-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Xinhua Chengdu, August 22 (Wang Peng) According to Chengdu Tianfu International Biocity 22 news, Sichuan University Huaxi Hospital Biotherm National Key Laboratory developed recombination protein new crown vaccine approved by the State Drug Administration clinical trials, this is China's first recombination protein produced by insect cells new crown vaccine.
    the vaccine targets SARS-CoV-2's prickly protein binding domain (S-RBD), producing a median antibody that blocks viral infections on human cells. The vaccine was tested in monkeys and other animals and found to have a good protective effect against SARS-CoV-2 infection, with no obvious side effects.
    the vaccine uses insect cells to multiply in culture, introducing genes from the new coronavirus into insect cells, which act as factories to produce high-quality recombinant vaccine proteins and purify them. The technology is easy to get fast and mass-produced vaccines to market.
    that the use of insects to produce recombinated protein vaccine, in Europe and the United States have cervical cancer vaccine and influenza vaccine and other products on the market, its application safety in the human body has been verified.
    In order to promote the clinical trial and market use of vaccines at an early stage, Chengdu Tianfu International Biological City to play the "major new drug creation of national science and technology major special results transfer transformation pilot demonstration base" advantages, at the beginning of the project research to maintain attention, close contact, after making initial progress and early intervention, design results transformation path.
    In April this year, Sichuan University Huaxi Hospital, vaccine research team and Tianfu International Biocity set up Chengdu Weisk Biopharmaceutical Co., Ltd., is planning and designing an annual output of hundreds of millions of needles production line, will achieve a full set of equipment domestic independent research and development.
    Chengdu Tianfu International Biocity City by Chengdu High-energy Zone and Shuangliu District, the planning area of about 44 square kilometers. Located in Chengdu Tianfu International Biological City, the vaccine industrialization project covers an area of 6000 square meters, is currently in the workshop design, equipment selection and environmental assessment work, the plant is expected to be put into use by the end of the year.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.